Oligometastatic non‐small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome

2025

Impact of Treatment Approaches on Oligometastatic Lung Cancer Outcomes

Sample size: 218 publication 10 minutes Evidence: moderate

Author Information

Author(s): Wiesweg Marcel, Küter Claudia, Schnorbach Johannes, Keyl Julius, Metzenmacher Martin, Cvetkovic Jelena, Saalfeld Felix Carl, Glanemann Franziska, Eberhardt Wilfried, Oezkan Filiz, Theegarten Dirk, Stenzinger Albrecht, Darwiche Kaid, Koschel Dirk, Herth Felix, Bölükbas Servet, Winter Hauke, Weykamp Fabian, Wermke Martin, Stuschke Martin, Plönes Till, Thomas Michael, Schuler Martin, Christopoulos Petros

Primary Institution: West German Cancer Center, University Hospital Essen

Hypothesis

What is the impact of local and systemic treatment approaches on clinical outcomes in patients with oligometastatic non-small cell lung cancer?

Conclusion

Patients with oligometastatic non-small cell lung cancer benefit from multimodal treatment approaches that include both systemic therapy and local ablation.

Supporting Evidence

Overall survival was significantly longer with a single metastatic lesion.
Patients who completed local ablative therapy had a median overall survival of 34.4 months.
Systemic treatment as part of first-line therapy was associated with doubling of recurrence-free survival.
Adding checkpoint inhibitors to chemotherapy greatly improved recurrence-free survival.

Takeaway

This study shows that patients with a specific type of lung cancer can live longer if they get a mix of treatments that attack the cancer in different ways.

Methodology

This real-world study analyzed clinical data from 218 patients with oligometastatic non-small cell lung cancer treated at three major German cancer centers from 2004 to 2023.